LG

LG Life Sciences’ ‘Follitrope’, treatment for controlled ovarian hyperstimulation developed using Recombinant DNA Technology to treat infertility, has entered the Chinese medicine market. ‘Follitrope’ has stable medicinal effect compared to previous follicle stimulating hormone products, and is proved for its safeness and effectiveness. LG Life Sciences has recently signed a sales contract with China’s Weijian Pharma Group on ‘Follitrope’. Weijan Pharma Group will exclusively conduct clinical trial, registration and sales on Follitrope in China, and LG Life Sciences will deliver finished products after the initial technology fees are paid and every major milestone at each phase is picked up for registration.